Song Qian-Qian, Xie Wan-Ying, Tang Yong-Jun, Zhang Jun, Liu Jie
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P.R. China.
Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, Hunan, P.R. China.
Pharmacogenomics. 2017 Feb;18(3):293-316. doi: 10.2217/pgs-2016-0151. Epub 2017 Jan 23.
Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases. However, in a subgroup of patients, failure to respond to GCs is known as GC resistance or GC insensitivity. This represents an important barrier to effective treatment and a clinical problem requiring an urgent solution. Genetic variation in the GC pathway is a significant factor in interindividual differences in GC treatment. This article reviews the pharmacogenetics of GCs in diverse diseases based on the GC pathway.
糖皮质激素（GCs）被广泛用于治疗哮喘、类风湿性关节炎、肾病综合征、急性淋巴细胞白血病和其他自身免疫性疾病。然而，在一部分患者中，对GCs无反应被称为GC抵抗或GC不敏感。这是有效治疗的一个重要障碍，也是一个亟待解决的临床问题。GC途径中的基因变异是GC治疗个体差异的一个重要因素。本文基于GC途径综述了GCs在多种疾病中的药物遗传学。
